Synthetic anticancer gene medicine exploits intrinsic antitumor activity of cationic vector to cure established tumors

Cancer Research

Volumn 65, Issue 18, 2005, Pages 8079-8084

  Dufès, Christine ^a   Keith, W Nicol ^a   Bilsland, Alan ^a   Proutski, Irina ^a   Uchegbu, Ijeoma F ^b   Schätzlein, Andreas G ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b UNIVERSITY OF STRATHCLYDE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DENDRIMER; DRUG VEHICLE; NANOPARTICLE; POLYPROPYLENIMINE DENDRIMER; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER SURVIVAL; COLORECTAL CARCINOMA; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; DRUG TOLERABILITY; FEMALE; GENE; GENE DELIVERY SYSTEM; GENE EXPRESSION; GENE THERAPY; MOUSE; NONHUMAN; PLASMID; PRIORITY JOURNAL; PROMOTER REGION; SQUAMOUS CELL CARCINOMA; TNFALPHA GENE; TRANSGENE; TUMOR REGRESSION; TUMOR XENOGRAFT; UTERINE CERVIX CARCINOMA;

ADENOCARCINOMA; ANIMALS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; FEMALE; GENE THERAPY; GENETIC VECTORS; HUMANS; LAC OPERON; NANOSTRUCTURES; NEOPLASMS; PLASMIDS; POLYPROPYLENES; PROMOTER REGIONS (GENETICS); TRANSFECTION; TUMOR NECROSIS FACTOR-ALPHA; UTERINE CERVICAL NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 24944434257     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-4402     Document Type: Article

References (20)

1. Niidome T, Huang L. Gene therapy progress and prospects: nonviral vectors. Gene Ther 2002;9:1647-52.
2. Thomas CE, Ehrhardt A, Kay MA. Progress and problems with the use of viral vectors for gene therapy. Nat Rev Genet 2003;4:346-58.
3. Jain RK. Delivery of molecular and cellular medicine to solid tumors. J Control Release 1998;53:49-67,
4. Dufes C, Muller JM, Couet W, Olivier JC, Uchegbu IF, Schatzlein AG. Anticancer drug delivery with transferrin targeted polymeric chitosan vesicles. Pharm Res 2004;21:101-7.
5. Plumb JA, Bilsland A, Kakani R, et al. Telomerase-specific suicide gene therapy vectors expressing bacterial nitroreductase sensitize human cancer cells to the pro-drug CB1954. Oncogene 2001;20:7797-803.
6. Zinselmeyer BH, Beggbie N, Uchegbu IF, Schatzlein AG. Quantification of β-galactosidase activity after non-viral transfection in vivo. J Control Release 2003;91:201-8.
7. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-16.
8. Boussif O, Lezoualc'h F, Zanta MA, et al. A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine. Proc Natl Acad Sci U S A 1995;92:7297-301.
9. Tang MX, Redemann CT, Szoka FC. In vitro gene delivery by degraded polyamidoamine dendrimers. Bioconjug Chem 1996;7:703-14.
10. Zinselmeyer BH, Mackay SP, Schatzlein AG, Uchegbu IF. The lower-generation polypropylenimine dendrimers are effective gene-transfer agents. Pharm Res 2002;19:960-7.
11. Hollins AJ, Benboubetra M, Omidi Y, et al. Evaluation of generation 2 and 3 poly(propylenimine) dendrimers for the potential cellular delivery of antisense oligonucleotides targeting the epidermal growth factor receptor. Pharm Res 2004;21:458-66.
12. Schätzlein AG, Zinselmeyer BH, Elouzi A, et al. Preferential liver gene expression with polypropylenimine dendrimers. J Control Release 2004;101:247-58.
13. Tracey KJ, Cerami A. Tumor necrosis factor: a pleiotropic cytokine and therapeutic target. Annu Rev Med 1994;45:491-503.
14. Grunhagen DJ, Brunstein F, ten Hagen TL, van Geel AN, de Wilt JH, Eggermont AM. TNF-based isolated limb perfusion: a decade of experience with antivascular therapy in the management of locally advanced extremity soft tissue sarcomas. Cancer Treat Res 2004;120:65-79.
15. Robson T, Hirst DG. Transcriptional targeting in cancer gene therapy. J Biomed Biotechnol 2003;2003:110-37.
16. Bilsland AE, Anderson CJ, Fletcher-Monaghan AJ, et al. Selective ablation of human cancer cells by telomerase-specific adenoviral suicide gene therapy vectors expressing bacterial nitroreductase. Oncogene 2003;22:370-80.
17. Curnis F, Sacchi A, Corti A. Improving chemotherapeutic drug penetration in tumors by vascular targeting and barrier alteration. J Clin Invest 2002;110:475-82.
18. Groot-Wassink T, Aboagye EO, Wang Y, Lemoine NR, Keith WN, Vassaux G. Noninvasive imaging of the transcriptional activities of human telomerase promoter fragments in mice. Cancer Res 2004;64:4906-11.
19. Kircheis R. Wightman L, Kursa M, Ostermann E, Wagner E. Tumor-targeted gene delivery: an attractive strategy to use highly active effector molecules in cancer treatment. Gene Ther 2002;9:731-5.
20. Senzer N, Mani S, Rosemurgy A, et al. TNFerade biologic, an adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor α gene: a phase I study in patients with solid tumors. J Clin Oncol 2004;22:592-601.